ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: The pioneering example of molecularly driven cancer medicine was the development and use of the kinase inhibitor imatinib for the treatment of chronic myelogenous leukemias that harbor the BCR-ABL1 balanced chromosomal translocation [169].